Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 11/20 | 0.54 |
| ▸ | ADH1C | P00326 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ADH1B | P00325 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ADH4 | P08319 | 2/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957190 | 1.00 | ADH1A (0.54) | ADH1AADH1CKDM4EADH1BHRH4 | |
| SCHEMBL29957698 | 0.98 | ADH1A (0.50) | ADH1AADH1CKDM4EADH1BHRH4 | |
| SCHEMBL29955741 | 0.87 | — | — | |
| SCHEMBL29951006 | 0.80 | ADH1A (0.48) | ADH1AADH1CKDM4EADH1BHRH4 | |
| SCHEMBL3683421 | 0.79 | KDM4E (0.47) | ADH1AADH1CKDM4EADH1BHRH4 | |
| SCHEMBL29956564 | 0.79 | KDM4E (0.33) | ADH1AADH1CKDM4EADH4 | |
| SCHEMBL29954517 | 0.77 | ADH1A (0.45) | ADH1AADH1CKDM4EADH1BHRH4 | |
| SCHEMBL29954046 | 0.77 | NOS3 (0.36) | ADH1AADH1CKDM4E | |
| SCHEMBL8445896 | 0.76 | KDM4E (0.44) | ADH1AADH1CKDM4EHRH4HRH3 | |
| SCHEMBL3936586 | 0.76 | KDM4E (0.41) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-4329347-A | Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril | BOEHRINGER INGELHEIM GMBH (DE) | 1982-05-11 | — | — | US | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| CN-1016869-B | Process for preparing 6, 7-diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1992-06-03 | — | — | CN | disclosed |
| CN-1030583-A | Preparation 6,7-diacyl-7-takes off the novel method of acetyl forskrine derivant | NIPPON KAYAKU KK (JP) | 1989-01-25 | — | — | CN | disclosed |
| US-4329347-A | Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril | BOEHRINGER INGELHEIM GMBH (DE) | 1982-05-11 | — | — | US | disclosed |
| EP-0003771-A1 | Carbostyrile derivatives, their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1979-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | ADH1A 3186/4885ADH1C 3992/4885KDM4E 2576/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | ADH1A 1597/4885ADH1C 2579/4885KDM4E 2663/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ADH1A 2394/4885ADH1C 3974/4885KDM4E 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.